BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu H, Yang C, Lu W, Zeng Y. Prognostic significance of glypican-3 expression in hepatocellular carcinoma: A meta-analysis. Medicine (Baltimore) 2018;97:e9702. [PMID: 29369198 DOI: 10.1097/MD.0000000000009702] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Guizhen Z, Guanchang J, Liwen L, Huifen W, Zhigang R, Ranran S, Zujiang Y. The tumor microenvironment of hepatocellular carcinoma and its targeting strategy by CAR-T cell immunotherapy. Front Endocrinol 2022;13:918869. [DOI: 10.3389/fendo.2022.918869] [Reference Citation Analysis]
2 Zaidi S, Amdur R, Xiang X, Yu H, Wong LL, Rao S, He AR, Amin K, Zaheer D, Narayan RK, Satapathy SK, Latham PS, Shetty K, Guha C, Gough NR, Mishra L. Using quantitative immunohistochemistry in patients at high risk for hepatocellular cancer. Genes Cancer 2022;13:9-20. [PMID: 35677836 DOI: 10.18632/genesandcancer.220] [Reference Citation Analysis]
3 Baj J, Bryliński Ł, Woliński F, Granat M, Kostelecka K, Duda P, Flieger J, Teresiński G, Buszewicz G, Furtak-Niczyporuk M, Portincasa P. Biomarkers and Genetic Markers of Hepatocellular Carcinoma and Cholangiocarcinoma-What Do We Already Know. Cancers (Basel) 2022;14:1493. [PMID: 35326644 DOI: 10.3390/cancers14061493] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Huang SL, Wang YM, Wang QY, Feng GG, Wu FQ, Yang LM, Zhang XH, Xin HW. Mechanisms and Clinical Trials of Hepatocellular Carcinoma Immunotherapy. Front Genet 2021;12:691391. [PMID: 34306031 DOI: 10.3389/fgene.2021.691391] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
5 Peng X, Lei C, He A, Luo R, Cai Y, Dong W. Upregulation of phosphatidylinositol glycan anchor biosynthesis class C is associated with unfavorable survival prognosis in patients with hepatocellular carcinoma. Oncol Lett 2021;21:237. [PMID: 33613726 DOI: 10.3892/ol.2021.12498] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Wei J, Hu M, Huang K, Lin S, Du H. Roles of Proteoglycans and Glycosaminoglycans in Cancer Development and Progression. Int J Mol Sci 2020;21:E5983. [PMID: 32825245 DOI: 10.3390/ijms21175983] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
7 Li N, Spetz MR, Ho M. The Role of Glypicans in Cancer Progression and Therapy. J Histochem Cytochem 2020;68:841-62. [PMID: 32623934 DOI: 10.1369/0022155420933709] [Cited by in Crossref: 8] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
8 Piñero F, Dirchwolf M, Pessôa MG. Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment. Cells 2020;9:E1370. [PMID: 32492896 DOI: 10.3390/cells9061370] [Cited by in Crossref: 12] [Cited by in F6Publishing: 64] [Article Influence: 6.0] [Reference Citation Analysis]
9 Yorita K, Ohno A, Nishida T, Kondo K, Ohtomo T, Kataoka H. Intratumoral reciprocal expression of monocarboxylate transporter 4 and glypican-3 in hepatocellular carcinomas. BMC Res Notes 2019;12:741. [PMID: 31706332 DOI: 10.1186/s13104-019-4778-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
10 Kolluri A, Ho M. The Role of Glypican-3 in Regulating Wnt, YAP, and Hedgehog in Liver Cancer. Front Oncol 2019;9:708. [PMID: 31428581 DOI: 10.3389/fonc.2019.00708] [Cited by in Crossref: 24] [Cited by in F6Publishing: 36] [Article Influence: 8.0] [Reference Citation Analysis]
11 Hamaoka M, Kobayashi T, Tanaka Y, Mashima H, Ohdan H. Clinical significance of glypican-3-positive circulating tumor cells of hepatocellular carcinoma patients: A prospective study. PLoS One. 2019;14:e0217586. [PMID: 31141571 DOI: 10.1371/journal.pone.0217586] [Cited by in Crossref: 16] [Cited by in F6Publishing: 25] [Article Influence: 5.3] [Reference Citation Analysis]
12 Moudi B, Heidari Z, Mahmoudzadeh-Sagheb H. Meta-analysis and systematic review of prognostic significance of Glypican-3 in patients with hepatitis B-related hepatocellular carcinoma. Virusdisease 2019;30:193-200. [PMID: 31179356 DOI: 10.1007/s13337-019-00517-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
13 Dong JJ, Ying L, Shi KQ. Expression of the Wnt ligands gene family and its relationship to prognosis in hepatocellular carcinoma. Cancer Cell Int 2019;19:34. [PMID: 30814912 DOI: 10.1186/s12935-019-0743-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
14 Tanaka Y, Tateishi R, Koike K. Proteoglycans Are Attractive Biomarkers and Therapeutic Targets in Hepatocellular Carcinoma. Int J Mol Sci 2018;19:E3070. [PMID: 30297672 DOI: 10.3390/ijms19103070] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]